Latest news with #BauschLomb
Reuters
3 days ago
- Business
- Reuters
US FDA approves Alcon's new dry-eye drug
May 28 (Reuters) - Eye-care drugmaker Alcon (ALCC.S), opens new tab said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED). Spun off from Novartis (NOVN.S), opens new tab in 2019, Alcon is betting on new product launches to accelerate sales growth in the second half of 2025 and beyond. The approval was based on late-stage studies in which the liquid medication, Tryptyr, demonstrated natural tear production as early as day one. The company said Tryptyr stimulates corneal sensory nerves to quickly increase natural tear production. DED is a condition in which the eyes either do not produce enough tears or produce poor-quality tears, leading to discomfort and potentially affecting vision. The company said about 38 million individuals in the United States suffer from DED, yet fewer than 10% of diagnosed patients are being treated with a prescription product. Alcon, which produces contact lenses, dry eye drops, gels and other related products, expects to launch Tryptyr in the United States during the third quarter of 2025, with plans to introduce the treatment in other markets later. Other FDA-approved treatments for DED include Alcon's Eysuvis and Bausch + Lomb's ( opens new tab Xiidra. Last month, however, the FDA declined to approve Aldeyra Therapeutics' (ALDX.O), opens new tab treatment for DED.
Yahoo
23-05-2025
- Business
- Yahoo
3 Reasons to Avoid BLCO and 1 Stock to Buy Instead
Shareholders of Bausch + Lomb would probably like to forget the past six months even happened. The stock dropped 42.8% and now trades at $11.19. This was partly driven by its softer quarterly results and might have investors contemplating their next move. Is now the time to buy Bausch + Lomb, or should you be careful about including it in your portfolio? Check out our in-depth research report to see what our analysts have to say, it's free. Even with the cheaper entry price, we're swiping left on Bausch + Lomb for now. Here are three reasons why we avoid BLCO and a stock we'd rather own. Reviewing a company's long-term sales performance reveals insights into its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Regrettably, Bausch + Lomb's sales grew at a mediocre 5.3% compounded annual growth rate over the last five years. This was below our standard for the healthcare sector. Free cash flow isn't a prominently featured metric in company financials and earnings releases, but we think it's telling because it accounts for all operating and capital expenses, making it tough to manipulate. Cash is king. As you can see below, Bausch + Lomb's margin dropped by 20.6 percentage points over the last five years. This along with its unexciting margin put the company in a tough spot, and shareholders are likely hoping it can reverse course. If the trend continues, it could signal it's becoming a more capital-intensive business. Bausch + Lomb's free cash flow margin for the trailing 12 months was negative 3.5%. As long-term investors, the risk we care about most is the permanent loss of capital, which can happen when a company goes bankrupt or raises money from a disadvantaged position. This is separate from short-term stock price volatility, something we are much less bothered by. Bausch + Lomb burned through $168 million of cash over the last year, and its $4.83 billion of debt exceeds the $215 million of cash on its balance sheet. This is a deal breaker for us because indebted loss-making companies spell trouble. Unless the Bausch + Lomb's fundamentals change quickly, it might find itself in a position where it must raise capital from investors to continue operating. Whether that would be favorable is unclear because dilution is a headwind for shareholder returns. We remain cautious of Bausch + Lomb until it generates consistent free cash flow or any of its announced financing plans materialize on its balance sheet. Bausch + Lomb isn't a terrible business, but it doesn't pass our quality test. After the recent drawdown, the stock trades at 14.1× forward P/E (or $11.19 per share). Investors with a higher risk tolerance might like the company, but we don't really see a big opportunity at the moment. We're fairly confident there are better investments elsewhere. Let us point you toward an all-weather company that owns household favorite Taco Bell. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
National Post
22-05-2025
- Business
- National Post
Bausch + Lomb to Participate in the 2025 Jefferies Global Healthcare Conference
Article content VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chief Financial Officer Sam Eldessouky is scheduled to participate in the 2025 Jefferies Global Healthcare Conference in New York City on June 4, 2025, at 7:35 a.m. ET. Article content Article content A live webcast of the conference will be available on the Investor Relations section of the Bausch + Lomb website. Article content About Bausch + Lomb Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit and connect with us on Facebook, Instagram, LinkedIn, X and YouTube. Article content Article content Article content Article content Article content Contacts Article content Media Contact: Chris Clark (848) 360-1100 Article content Article content
National Post
21-05-2025
- Business
- National Post
Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results
Article content VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX: BLCO) ('Bausch + Lomb' or the 'Company'), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2025 Annual Meeting of Shareholders (the 'Annual Meeting') held on May 21, 2025. Detailed results of the vote follow: Article content Article content Name For Against Broker Non-Votes Nathalie Bernier 337,617,248 1,924,336 8,383,437 Gary Hu 337,591,706 1,949,878 8,383,437 Brett Icahn 337,474,287 2,067,297 8,383,437 Sarah B. Kavanagh 337,602,211 1,939,373 8,383,437 Karen L. Ling 337,526,114 2,015,470 8,383,437 John A. Paulson 337,650,735 1,890,849 8,383,437 Russel C. Robertson 337,600,880 1,940,704 8,383,437 Thomas W. Ross, Sr. 337,583,018 1,958,566 8,383,437 Brenton L. Saunders 337,592,062 1,949,522 8,383,437 Andrew C. von Eschenbach, M.D. 337,607,276 1,934,308 8,383,437 Article content Shareholders also approved, in a non-binding advisory vote, the compensation of the Company's named executive officers, appointment of PricewaterhouseCoopers LLP to serve as auditor until the close of the Company's 2026 Annual Meeting of Shareholders, and authorization for the board of directors to fix the auditor's remuneration. Article content The final vote tabulation on all matters voted on at the Annual Meeting will be filed with the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company's SEDAR+ profile and on the Company's website at Article content About Bausch + Lomb Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit and connect with us on Facebook, Instagram, LinkedIn, X and YouTube. Article content Article content Article content Article content Article content Contacts Article content Media Contact: Chris Clark (848) 360-1100 Article content Article content Article content
National Post
21-05-2025
- Health
- National Post
Bausch + Lomb Launches New LUMIFY® Preservative Free Redness Reliever Eye Drops in the United States
Article content VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of LUMIFY Preservative Free redness reliever eye drops, the first and only preservative-free over-the-counter eye drops with low-dose brimonidine tartrate 0.025% that relieve redness of the eye due to minor eye irritations. Article content Article content 'Consumers often say how amazed they are at the difference our original LUMIFY makes to their eyes, with over 50,000 five-star reviews as proof,' said John Ferris, president, Consumer, Bausch + Lomb. 'LUMIFY Preservative Free brings that same fast-acting formula to those with sensitive eyes — delivering a visibly brighter, whiter look in just 60 seconds.' Article content Before LUMIFY eye drops were introduced in 2018, redness relievers relied on the same ingredients for decades, which had well known side effects. LUMIFY and LUMIFY Preservative Free are the only over-the-counter redness relievers that selectively target eye redness and offer excellent results with a lower risk of rebound redness and loss of efficacy when used as directed. Article content 'LUMIFY delivers consistently proven results for patients experiencing eye redness,' said Melissa Toyos, MD, and partner, Toyos Clinic, Nashville, TN. 'With LUMIFY Preservative Free, my patients with eye sensitivities now have an option that's just as effective as the original LUMIFY redness reliever eye drops.' Article content LUMIFY Preservative Free is now available in convenient single-use vials at most U.S. retailers nationwide, including Walmart, Target, CVS, Walgreens, Rite Aid and Amazon. The eye drops will have a manufacturer's suggested retail price of $26.99 and feature updated premium packaging consistent with LUMIFY. Article content About the LUMIFY Brand The LUMIFY brand began in 2018 with the U.S. launch of LUMIFY redness reliever eye drops. They are the No. 1 eye doctor recommended redness reliever eye drop brand with approximately 90% of doctor recommendations 1 and have grown double digits every year since launching. In 2023, Bausch + Lomb introduced LUMIFY EYE ILLUMINATIONS™, a line of specialty eye care products specifically developed for the sensitive area around the eyes. The FDA approved LUMIFY Preservative Free eye drops in April 2024. For more information on the LUMIFY brand, visit Article content About Bausch + Lomb Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit and connect with us on Facebook, Instagram, LinkedIn, X and YouTube. Article content Article content Article content Article content Article content Contacts Article content Article content Article content
